The significance of defining preclinical or prodromal Parkinson's disease.
Identifieur interne : 000B73 ( Main/Merge ); précédent : 000B72; suivant : 000B74The significance of defining preclinical or prodromal Parkinson's disease.
Auteurs : C Warren Olanow [États-Unis] ; José A. ObesoSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2012.
English descriptors
- KwdEn :
- MESH :
- diagnosis : Parkinson Disease.
- etiology : Parkinson Disease.
- therapy : Parkinson Disease.
- Clinical Trials as Topic, Early Diagnosis, Humans.
Abstract
A body of clinical and pathologic evidence supports the concept that there a pre-Parkinson state exists prior to the time when Parkinson's disease (PD) can be formally diagnosed. The ability to define a the preclinical or prodromal PD state has many important implications. First, understanding the timing and sequence of pathologic change that occurs in PD could provide important clues as to the etiology and pathogenesis of PD, and provide insight into cell vulnerability factors. Second, defining a population of patients with preclinical PD would provide a potentially important group of subjects for clinical trials attempting to define disease-modifying therapies. And, finally, being able to determine that a person has PD at an earlier time point than is currently possible would permit the introduction of a putative disease-modifying therapy at a time when it could have more profound and long-lasting effects. This paper reviews the clinical significance of defining preclinical PD.
DOI: 10.1002/mds.25019
PubMed: 22508285
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E02
- to stream PubMed, to step Curation: 000E02
- to stream PubMed, to step Checkpoint: 000B80
- to stream Ncbi, to step Merge: 003628
- to stream Ncbi, to step Curation: 003628
- to stream Ncbi, to step Checkpoint: 003628
Links to Exploration step
pubmed:22508285Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The significance of defining preclinical or prodromal Parkinson's disease.</title>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA. cwolanow@movementdisorders.org</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Obeso, Jose A" sort="Obeso, Jose A" uniqKey="Obeso J" first="José A" last="Obeso">José A. Obeso</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="doi">10.1002/mds.25019</idno>
<idno type="RBID">pubmed:22508285</idno>
<idno type="pmid">22508285</idno>
<idno type="wicri:Area/PubMed/Corpus">000E02</idno>
<idno type="wicri:Area/PubMed/Curation">000E02</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B80</idno>
<idno type="wicri:Area/Ncbi/Merge">003628</idno>
<idno type="wicri:Area/Ncbi/Curation">003628</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003628</idno>
<idno type="wicri:Area/Main/Merge">000B73</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The significance of defining preclinical or prodromal Parkinson's disease.</title>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA. cwolanow@movementdisorders.org</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Obeso, Jose A" sort="Obeso, Jose A" uniqKey="Obeso J" first="José A" last="Obeso">José A. Obeso</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Early Diagnosis</term>
<term>Humans</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (etiology)</term>
<term>Parkinson Disease (therapy)</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Early Diagnosis</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A body of clinical and pathologic evidence supports the concept that there a pre-Parkinson state exists prior to the time when Parkinson's disease (PD) can be formally diagnosed. The ability to define a the preclinical or prodromal PD state has many important implications. First, understanding the timing and sequence of pathologic change that occurs in PD could provide important clues as to the etiology and pathogenesis of PD, and provide insight into cell vulnerability factors. Second, defining a population of patients with preclinical PD would provide a potentially important group of subjects for clinical trials attempting to define disease-modifying therapies. And, finally, being able to determine that a person has PD at an earlier time point than is currently possible would permit the introduction of a putative disease-modifying therapy at a time when it could have more profound and long-lasting effects. This paper reviews the clinical significance of defining preclinical PD.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 000B73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= pubmed:22508285 |texte= The significance of defining preclinical or prodromal Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:22508285" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |